Bristol Myers Squibb Company $BMY Shares Acquired by Hudson Edge Investment Partners Inc.

Hudson Edge Investment Partners Inc. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 16.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 168,767 shares of the biopharmaceutical company’s stock after acquiring an additional 23,799 shares during the period. Bristol Myers Squibb accounts for approximately 1.3% of Hudson Edge Investment Partners Inc.’s investment portfolio, making the stock its 9th biggest holding. Hudson Edge Investment Partners Inc.’s holdings in Bristol Myers Squibb were worth $9,103,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at about $35,000. JPL Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at about $36,000. Finally, Beacon Financial Strategies CORP acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $38,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 0.1%

Bristol Myers Squibb stock opened at $60.21 on Monday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market cap of $122.93 billion, a price-to-earnings ratio of 17.45, a P/E/G ratio of 0.17 and a beta of 0.27. The firm has a fifty day moving average price of $59.82 and a two-hundred day moving average price of $53.73.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the company posted $1.67 earnings per share. The firm’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on BMY. Leerink Partners boosted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. HSBC boosted their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Citigroup boosted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Bank of America reduced their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.71.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.